SMS Lifesciences India Limited Asset Resilience Ratio

Latest as of September 2025: 0.26%

SMS Lifesciences India Limited asset resilience ratio. SMS Lifesciences India Limited (SMSLIFE) has an Asset Resilience Ratio of 0.26% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SMSLIFE days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Rs10.32 Million
≈ $111.59K USD Cash + Short-term Investments

Total Assets

Rs3.94 Billion
≈ $42.60 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of SMS Lifesciences India Limited (2017–2025)

Asset resilience ratio of SMS Lifesciences India Limited from 2017 to 2025. This chart shows how SMS Lifesciences India Limited's Asset Resilience Ratio has changed over time. Read debt load of SMS Lifesciences India Limited for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down SMS Lifesciences India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SMS Lifesciences India Limited balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs10.32 Million 0.26%
Total Liquid Assets Rs10.32 Million 0.26%

Asset Resilience Insights

  • Limited Liquidity: SMS Lifesciences India Limited maintains only 0.26% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

SMS Lifesciences India Limited Industry Peers by Asset Resilience Ratio

Compare SMS Lifesciences India Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

SMS Lifesciences India Limited Asset Resilience Ratio by Year (2017–2025)

SMS Lifesciences India Limited asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for SMS Lifesciences India Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.52% Rs20.10 Million
≈ $217.42K
Rs3.90 Billion
≈ $42.18 Million
+0.04pp
2024-03-31 0.47% Rs18.46 Million
≈ $199.64K
Rs3.91 Billion
≈ $42.23 Million
-0.69pp
2023-03-31 1.17% Rs39.38 Million
≈ $425.87K
Rs3.37 Billion
≈ $36.49 Million
+0.50pp
2022-03-31 0.66% Rs23.70 Million
≈ $256.28K
Rs3.57 Billion
≈ $38.58 Million
-0.03pp
2021-03-31 0.69% Rs20.89 Million
≈ $225.93K
Rs3.02 Billion
≈ $32.69 Million
+0.69pp
2020-03-31 0.00% Rs79.00K
≈ $854.36
Rs2.53 Billion
≈ $27.34 Million
+0.01pp
2019-03-31 0.00% Rs-79.00K
≈ $-854.36
Rs2.70 Billion
≈ $29.19 Million
+1.93pp
2018-03-31 -1.93% Rs-34.12 Million
≈ $-368.98K
Rs1.77 Billion
≈ $19.10 Million
+1.32pp
2017-03-31 -3.25% Rs-57.41 Million
≈ $-620.85K
Rs1.77 Billion
≈ $19.12 Million
--
pp = percentage points

About SMS Lifesciences India Limited

NSE:SMSLIFE India Biotechnology
Market Cap
$42.13 Million
Rs3.90 Billion INR
Market Cap Rank
#22332 Global
#1226 in India
Share Price
Rs1288.50
Change (1 day)
-6.64%
52-Week Range
Rs1150.70 - Rs1437.90
All Time High
Rs1747.88
About

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more